A total of 2,291 patients with drug-eluting stent implantation for ACS or SAP (n = 1,804) who underwent noncardiac surgery were compared with a cohort from the general population without known coronary artery disease. The patients were matched according to the surgical procedure, hospital contact type, gender, and age. The 30-day MI risk markedly increased when surgery was performed within 1 month after stenting, in patients with acute coronary syndrome (10% vs 0.8%; adjusted odds ratio [ORadj] 20.1, 95% confidence interval [CI] 8.85 to 45.6). The mortality, however, was comparable (10% vs 8%, ORadj 1.17, 95% CI 0.76 to 1.79). The 30-day absolute risk for MI was low but higher than in the comparison cohort (0.6% vs 0.2%, ORadj 2.18, 95% CI 0.89 to 5.38), when surgery was performed between 1 and 12 months after stenting. The mortality risks were similar (2.0% vs 1.8%, ORadj 1.03, 95% CI 0.69 to 1.55). The 30-day MI risk was low but higher than in the comparison cohort (0.4% vs 0.2%, ORadj 1.90, 95% CI 0.70 to 5.14), in patients with SAP. However, the mortality risks were similar However, the mortality risks were similar (2.2% vs 2.1%, ORadj 0.91, 95% CI 0.61 to 1.37).
Patients with acute coronary syndrome and stable angina pectoris who underwent surgery between 1- and 12-months following stent implantation had a risk for MI and death similar to the risk observed in surgical patients without coronary artery disease.